{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-123295","form_type":"8-K","ticker":"VSTM","cik":"0001526119","company_name":"Verastem, Inc.","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.631511+00:00","generated_at":"2026-05-16T12:33:46.787213+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Verastem: new chairman, president of development appointed; COO departs; RAMP 301 enrollment complete","bullets":["John Johnson appointed chairman of board; Michael Kauffman, MD, PhD, becomes president of development, leaving lead director role.","Matthew Ros, COO, departs; receives nine-month base salary continuation and pro-rated bonus under separation agreement.","RAMP 301 Phase 3 trial in recurrent LGSOC completed additional enrollment of 29 patients; topline data expected mid-2027.","Commercial launch of AVMAPKI FAKZYNJA CO-PACK progressing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-123295","json":"https://secwatch.observer/filing/0001104659-25-123295.json","markdown":"https://secwatch.observer/filing/0001104659-25-123295.md","text":"https://secwatch.observer/filing/0001104659-25-123295.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925123295/0001104659-25-123295-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1526119/000110465925123295/tm2533463d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:33:46.787213+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}